Alzamend Neuro Files Proxy Statement Amendment
Ticker: ALZN · Form: DEFA14A · Filed: Mar 17, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | DEFA14A |
| Filed Date | Mar 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, amendment, shareholder-meeting
TL;DR
Alzamend Neuro filed proxy docs, shareholders vote soon.
AI Summary
Alzamend Neuro, Inc. filed an amendment (Amendment No. 1) to its Definitive Proxy Statement on March 17, 2025. This filing concerns the solicitation of proxies for its annual meeting of stockholders. The company is incorporated in Delaware and its fiscal year ends on April 30.
Why It Matters
This filing is crucial for shareholders as it provides updated information and details regarding the company's annual meeting, allowing them to make informed decisions about voting their shares.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement amendment and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- 0001214659-25-004459 (filing_id) — Accession Number
- 20250317 (date) — Filing Date
FAQ
What type of filing is this?
This is a Definitive Proxy Statement (DEFA14A), specifically Amendment No. 1.
Who is the filer?
The filer is Alzamend Neuro, Inc.
When was this filing made?
The filing was made on March 17, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on April 30.
What is the company's primary business classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 17, 2025 regarding Alzamend Neuro, Inc. (ALZN).